Glaukos Corporation · NYSE:GKOS
Glaukos — Investor Presentation (May 2017)
16 slides from Glaukos's investor presentation, May 15, 2017
Slide 1: May 2017
May 2017 © 2017 Glaukos Corporation.
Slide 2: Disclaimer
2 © 2017 Glaukos Corporation. DISCLAIMER All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe th
Slide 3: Glaucoma therapy is transforming
glaucoma therapy and highly successful launch global opportunity1 of current treatments of micro-scale 3 © 2017 Glaukos Corporation. istransforming LARGE MARKETUNMET NEEDDEMONSTRATED EXECUTIONJUST THE BEGINNING Growing $5bnSignificant drawbacksBroad reimbursementAdvanced portfolio injectable therapi
Slide 4: Recent Accomplishments
1 >40% YoY growth since US commercialization 4 trial for standalone iStent inject® technologies direct markets to 13 4 © 2017 Glaukos Corporation. Recent Accomplishments Reported 55% quarterly global net sales growth in Q1 2017, delivering 15th consecutive quarter of 2Achieved gross margin in mid-80
Slide 5: Aging Population Drives Glaucoma Prevalence
Reducing treatment IOP is the only proven for glaucoma 3 intraocular pressure (IOP) 1 OAG 2016 2021 increase from 83mm in 2016 to 2016 2021 Open-Angle Glaucoma All Glaucoma 5 © 2017 Glaukos Corporation. Aging Population Drives Glaucoma Prevalence US GLAUCOMA POPULATION1 (in millions) 5 4 Typically a
Slide 6: How The Eye's Drainage System Works
© 2017 Glaukos Corporation. 6 How The Eye’s Drainage System Works Elevated IOP occurs whenSecondary outflow pathway is aqueous humor outflow throughthe suprachoroidal space the trabecular meshwork and into Schlemm’s canal is reduced due to degeneration and obstruction
Slide 7: iStent vs. Conventional Surgery
© 2017 Glaukos Corporation. 7 iStent® vs. Conventional Surgery Conventional Surgery
Slide 8: Compelling Clinical Results: Single iStent + Cataract Surgery
AT 36 MONTHS… CONSISTENT COHORT THROUGH 3 YEARS (n=39) 24 Preop Month 12 Month 24 Month 36 86% decision to implant based on eyes followed through 36 mean number of 9 Mean IOP (mm Hg) © 2017 Glaukos Corporation. Compelling Clinical Results: Single iStent + Cataract Surgery Achieves < 15 mm Hg Through
Slide 9: Compelling Clinical Results: US Retrospective Studies of Single iStent
20 16.37 15.17 13.6 16 Preop 1M 6M 12M 18M 24M Group 3: IOP not controlled Group 2: IOP not controlled Group 1: IOP controlled 10 Mean IOP (mm Hg) Mean IOP (mm Hg) © 2017 Glaukos Corporation. Compelling Clinical Results: US Retrospective Studies of Single iStent + Cataract Surgery MEAN IOPMEAN IOP T
Slide 10: Compelling Clinical Results: International Study of 1, 2 and 3 iStents
Demonstrates potential Medications 14.1 14 groups with preoperative in standalone Mean preop medicated Mean preop IOP after Month 18 mean IOP 11 mm Hg © 2017 Glaukos Corporation. Compelling Clinical Results: International Study Shows IOP-Lowering Capability of 1, 2 and 3 iStents Mean IOP at 18 Month
Slide 11: Clinical Research Program Statistics
21 Prospective clinical trials currently underway Articles published in journals 12 © 2017 Glaukos Corporation. Clinical Research Program Statistics 60 peer-reviewed
Slide 12: Q1 2017 Financial & Operational Performance
$40 growth in international sales $20 $10 worldwide 13 © 2017 Glaukos Corporation. Q1 2017 Financial & Operational Performance: Growth Reflects iStent Adoption Trends TOTAL NET SALES (in millions) 15th consecutive quarter of at $35.9least 40% year-over-year growth $35in net sales $30 $25+55%Includes
Slide 13: Current & Future Potential MIGS Market Participants
14 © 2017 Glaukos Corporation. Current & Future Potential MIGS Market Participants ALCON CYPASS 6.35mm suprachoroidal device for implantation into supraciliary space using guidewire delivery (actual) IVANTIS HYDRUS 8mm nitinol scaffolding device implanted into Schlemm’s canal (image) ALLERGAN XEN (F
Slide 14: Financial Summary
(IN MILLIONS) manufacturing and cost structure global expansion 15 © 2017 Glaukos Corporation. Financial Summary NET SALESGROSS MARGIN Strong net sales growth, driven primarily by increases in trained doctors, same-store sales and pricing Ability to leverage efficient Continued investments in pipeli
Slide 15: Growth Strategies: Establishing MIGS as OAG Standard of Care
16 © 2017 Glaukos Corporation. Growth Strategies: Establishing MIGS as OAG Standard of Care 01020304 Increase US iStentSecure FDA approvalsDevelop, secureExtend global reach of adoption with seasonedwith expandedregulatory approval forMIGS-based platform sales force, broadindications for iStentand c
Slide 16: © 2017 Glaukos Corporation. 17
© 2017 Glaukos Corporation. 17